Metraipolis › archive › dc_14b301657bc8

Tislelizumab efficacy and safety compared to other anti-PD-1s: a network meta-analysis of first-line therapies for unresectable, locally advanced or… — Europe PMC PMID:41567215

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41567215
DOI
10.3389/fimmu.2025.1657085
License (as archived)
solo-consultazione
Archived
2026-11-07T00:58:38.995Z
SHA-256 of the archived text
6decfec5c65c832b546a027c8a730a57364fb58843f73963a560b5bc63e4af97
Stable URL of this page
https://metraipolis.com/documento/dc_14b301657bc8

How to cite

Tislelizumab efficacy and safety compared to other anti-PD-1s: a network meta-analysis of first-line therapies for unresectable, locally advanced or… — Europe PMC PMID:41567215 — Europe PMC (en), https://europepmc.org/article/MED/41567215 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_14b301657bc8 (Metraipolis archive dc_14b301657bc8, sha256 6decfec5c65c832b546a027c8a730a57364fb58843f73963a560b5bc63e4af97)
BibTeX
@misc{dc14b301657bc8,
  title = {Tislelizumab efficacy and safety compared to other anti-PD-1s: a network meta-analysis of first-line therapies for unresectable, locally advanced or… — Europe PMC PMID:41567215},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41567215},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_14b301657bc8; sha256 6decfec5c65c832b546a027c8a730a57364fb58843f73963a560b5bc63e4af97},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41567215. Agents can read the archived copy with the MCP tool read_document.